10x Genomics, Inc. insider Serge Saxonov reported the sale of 30,000 shares of the company’s Class A common stock on June 22, 2026, under a prearranged Rule 10b5-1 trading plan adopted on November 29, 2025. The Form 4 was filed June 24, 2026. The sales were reported as transaction code “S” open-market sales and were executed in multiple price bands. Saxonov sold 8,527 shares at a weighted-average price of $33.289 per share, with trades in that batch ranging from $32.75 to $33.74. He then sold 9,991 shares at a weighted-average price of $34.2815, with individual trades ranging from $33.76 to $34.71. A third sale covered 9,821 shares at a weighted-average price of $35.3159, with trades ranging from $34.86 to $35.82. The final reported sale was 1,661 shares at a weighted-average price of $36.1646, with trades ranging from $35.98 to $36.24. In total, the reported transactions generated approximately $1.04 million in gross proceeds before commissions and other expenses. After the first three reported sale lots, Saxonov’s disclosed beneficial ownership declined from 1,129,853 shares to 1,119,862 shares and then to 1,110,041 shares. Taking into account the final 1,661-share sale, his remaining ownership would be approximately 1,108,380 shares of 10x Genomics Class A common stock, based on the sequence of reported holdings. The filing notes that each weighted-average price reflects multiple trades and that Saxonov will provide full details on the number of shares sold at each separate price upon request by the SEC staff, the company, or a security holder. The use of a Rule 10b5-1 plan indicates the transactions were made under a pre-established trading arrangement, commonly used by insiders to sell shares according to preset terms.